Process for the preparation of CIC-1 chloride channel inhibitors
A novel chemical process synthesizes CIC-1 chloride channel inhibitors to treat neuromuscular disorders by restoring neuromuscular transmission and improving muscle function, addressing the inadequacies of existing treatments.
Patent Information
- Application Number
- JP2021569300
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-19
- Filing Date
- 2020-06-19
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-06-19
AI Technical Summary
There is a need for effective treatments for neuromuscular disorders such as myasthenia gravis and ALS, as well as for reversing neuromuscular blockade, which current technologies have not adequately addressed.
A novel chemical process is developed for synthesizing CIC-1 chloride channel inhibitors, which are compounds that can restore neuromuscular transmission and alleviate muscle weakness and fatigue by inhibiting the CIC-1 ion channel.
The synthesized CIC-1 chloride channel inhibitors effectively restore neuromuscular transmission and improve muscle function in neuromuscular disorders, as demonstrated by their ability to increase muscle force in vivo and inhibit the CIC-1 channel in biological models.
Smart Images

Figure 0007595945000025 
Figure 0007595945000026 
Figure 0007595945000027
Abstract
Description
[Technical field]
[0001] The present disclosure relates to novel chemical processes for the synthesis of CIC-1 chloride channel inhibitors. [Background technology]
[0002] The present disclosure relates to a chemical process for producing a compound that is a CIC-1 chloride channel inhibitor.As described in WO2016 / 202341, CIC-1 chloride channel inhibitors can be useful in treating neuromuscular disorders such as myasthenia gravis and ALS, or in reversing and / or alleviating neuromuscular blockade. Summary of the Invention
[0003] There is a need for CIC-1 chloride channel inhibitors to develop treatments for neuromuscular disorders.The present disclosure provides a novel industrially applicable process for the preparation of compounds of formula I. Compounds of formula I can inhibit CIC-1 ion channels and restore neuromuscular transmission, as evidenced by the data generated by the investigation of compounds set in the biological model described herein.Therefore, these compounds can be used to treat or improve muscle weakness and muscle fatigue in neuromuscular junction disorders caused by disease or neuromuscular blockers.
[0004] In one aspect, the present disclosure provides a compound of formula I
[0005] [ka] Formula I
[0006] For the preparation of the compound Step a), i) Formula II
[0007] [ka] Formula II
[0008] reacting a compound of the formula (I) with an acid or a base; and ii) isolating the compound of formula I from the reaction mixture. providing a process including In the formula, R 1 ~R 9 and n is as defined herein.
[0009] The present disclosure further relates to novel compounds of formula II, as defined herein. [Brief description of the drawings]
[0010] [Figure 1] Panel A illustrates the voltage protocol used to elicit currents in whole-cell patches of CHO cells expressing the human ClC-1 channel. Panel B shows representative whole-cell current traces from patched CHO cells expressing the human CIC-1 channel. Currents were elicited by applying the voltage protocol shown in Panel A. [Diagram 2] Panel A shows representative I / V plots of constant current density in CIC-1-expressing CHO cells before (circles) and after (squares) application of 100 μM of the CIC-1 inhibitor, 9-anthracenecarboxylic acid (9-AC, Sigma A89405). Panel B shows I / V plots of instantaneous tail current density from the same CIC-1-expressing CHO cells described in panel A before (circles) and after (squares) application of 100 μM 9-AC. [Diagram 3] Figure 3 shows representative plots of normalized instantaneous tail currents from a patch of CIC-1-expressing CHO cells before (circles) and after (squares) application of 100 μM 9-AC. The instantaneous tail currents at each voltage step were normalized to the maximum tail current obtained following a (+)120 mV voltage step and fitted to a Boltzmann function to determine the half-activation potential, V1 / 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] definition The term “C 1-3 Alkyl" and "C 1-5 "Alkyl" refers to an alkyl group, branched or unbranched, having 1 to 3 or 1 to 5 carbon atoms, respectively, including, but not limited to, methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl.
[0012] The term “C 2-5 "Alkenyl" refers to a branched or unbranched alkenyl group having 2 to 5 carbon atoms, two of which are connected by a double bond, including, but not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and isopentenyl.
[0013] The term “C 2-5 "Alkynyl" refers to a branched or unbranched alkynyl group having 2 to 5 carbon atoms, 2 of which are connected by a triple bond, including, but not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, buta-1,3-diynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, penta-2,4-diynyl, and penta-1,3-diynyl.
[0014] The term “C 3-5 Cycloalkyl" and "C 3-6 "Cycloalkyl" refers to groups containing mono- or bicyclic carbocyclic rings having 3 to 5 or 3 to 6 carbon atoms, respectively, and includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0015] Detailed Description The present disclosure provides a novel, industrially applicable process for the preparation of CIC-1 chloride channel inhibitors, compounds of formula I. The process allows for better control of impurities, reduces or eliminates the need for chromatographic steps, and has higher yields, thereby providing a better cost of goods.
[0016] Thus, in one aspect, the present disclosure provides a compound of formula I
[0017] [ka] Formula I
[0018] Step a) for the preparation of the compound i) Formula II
[0019] [ka] Formula II
[0020] reacting a compound of the formula (I) with an acid or a base; And ii) isolating the compound of formula I from the reaction mixture. providing a process including During the ceremony, -R 1 is selected from the group consisting of H, F, Cl, Br and I; -R 2 is C 1-5 Alkyl and C 3-5 cycloalkyl; -R 3 is selected from the group consisting of deuterium, F, Cl, Br and I; -R 4 is H, deuterium, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 3-5 cycloalkyl and C5 cycloalkenyl, each of which may optionally be one or more identical or different substituents R 7may be substituted with; -R 5 optionally one or more identical or different substituents R 8 C replaced by 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 alkynyl, optionally one or more, identical or different, substituents R 8 C replaced by 3-6 cycloalkyl, optionally one or more, identical or different, substituents R 9 and optionally one or more, identical or different, substituents R 9 benzyl substituted with; -R 6 is H, deuterium, C 1-5 Alkyl and C 3-5 cycloalkyl; -R 7 is deuterium, tritium, F, Cl, Br, I, CN, isocyanide, optionally one or more identical or different substituents R 8 C replaced by 3-5 cycloalkyl, optionally one or more, identical or different, substituents R 8 Replaced by OC 1-3 alkyl, optionally one or more, identical or different, substituents R 8 SC replaced by 1-3 alkyl, optionally one or more, identical or different, substituents R 8 CH2-OC substituted with 1-3 Alkyl and optionally one or more, identical or different, substituents R 8 CH2-SC substituted with 1-3 independently selected from the group consisting of alkyl; -R 8 are independently selected from the group consisting of deuterium and F; -R 9 is independently selected from the group consisting of deuterium, methoxy, nitro, cyano, Cl, Br, I and F; and -n is an integer of 0, 1, 2 or 3.
[0021] In one embodiment, R 1 is Cl or Br. In one embodiment, R 1 is Cl. In one embodiment, R 1 is Br.
[0022] In one embodiment, R 2 is C 1-5 In one embodiment, R 2 is selected from the group consisting of methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl. 2 is ethyl. In one embodiment, R 2 is prop-1-yl. In one embodiment, R 2 is prop-2-yl. In one embodiment, R 2 is but-1-yl. In one embodiment, R 2 is 2-methyl-prop-2-yl.
[0023] In one embodiment, R 3 is deuterium. In one embodiment, R 3 is F.
[0024] In one embodiment, R 4 is H. In one embodiment, R 4 optionally one or more identical or different substituents R 7 C replaced by 1-5 In one embodiment, R 4 optionally one or more identical or different substituents R 8 C replaced by 3-5 Cycloalkyl-substituted C 1-5 In one embodiment, R4 is Me. In one embodiment, R 4 is Et. In one embodiment, R 4 is -CHF. In one embodiment, R 5 is cyclopropyl.
[0025] In one embodiment, R 5 optionally one or more identical or different substituents R 8 C replaced by 1-5 In one embodiment, R 5 is Me. In one embodiment, R 5 is Et. In one embodiment, R 5 is 2-methyl-prop-2-yl.
[0026] In one embodiment, R 6 is H. In one embodiment, R 6 is deuterium. In one embodiment, R 6 is C 1-5 In one embodiment, R 6 is selected from the group consisting of methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl.
[0027] In one embodiment, R 7 is deuterium. In one embodiment, R 7 is F. In one embodiment, R 7 optionally one or more identical or different substituents R 8 C replaced by 3-5 In one embodiment, R 4 is R 7 C replaced by 1-5 is alkyl, R 7optionally one or more identical or different substituents R 8 C replaced by 3-5 It is cycloalkyl.
[0028] In one embodiment, n is 0. In one embodiment, n is 1. In one embodiment, n is 2. In one embodiment, n is 3.
[0029] In one embodiment, the compound of formula II is reacted with an acid. In one embodiment, the compound of formula II is reacted with a concentrated acid. In one embodiment, the compound of formula II is reacted with an acid selected from formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, hydrochloric acid, and sulfuric acid or mixtures thereof, for example, a mixture of formic acid and acetic acid. In one embodiment, the acid is acetic acid. In one embodiment, the acid is formic acid. In one embodiment, the acid is concentrated acetic acid. In one embodiment, the acid is concentrated formic acid. In one embodiment, the acid is concentrated acetic acid. In one embodiment, the acid is a mixture of concentrated formic acid and concentrated acetic acid.
[0030] In one embodiment, step a)i) is carried out at a temperature between 70°C and 140°C, such as between 80°C and 130°C, for example between 90°C and 120°C.
[0031] In one embodiment, the reaction time of step a)i) is from 12 hours to 96 hours, such as from 24 hours to 72 hours, for example from 36 hours to 60 hours.
[0032] In one embodiment, the amount of acid used in step a) i) is from 3 mL per gram of starting material to 15 mL per gram of starting material.
[0033] In one embodiment, the compound of formula I is isolated from the reaction mixture by adding water and extracting the product into an organic solvent. In one embodiment, the organic solvent used for extraction is selected from the list consisting of toluene, ethyl acetate, isopropyl acetate and tert-butyl methyl ether. In one embodiment, the organic solvent used for extraction is tert-butyl methyl ether.
[0034] In one embodiment, the compound of formula I is purified by crystallization from an organic solvent selected from the list consisting of toluene, ethyl acetate, isopropyl acetate and tert-butyl methyl ether. In one embodiment, the compound of formula I is purified by crystallization from toluene.
[0035] In one embodiment, the process further comprises step b): i) Formula III
[0036] [ka] Formula III
[0037] reacting the compound of formula (I) with N-chlorosuccinimide in an organic solvent; ii) Formula IV
[0038] [ka] Formula IV
[0039] and a base to the reaction mixture; and iii) isolating the compound of formula II from the reaction mixture. Including, In the formula, R 1 ~R 9 and n is as defined herein.
[0040] In one embodiment, the solvent in step b)i) is dimethylformamide (DMF). In one embodiment, the compound of formula IV is selected from the group consisting of ethyl vinyl ether, n-butyl vinyl ether, and tert-butyl vinyl ether. In one embodiment, the compound of formula IV is n-butyl vinyl ether. In one embodiment, the base in step b)ii) is a trialkylamine. In one embodiment, the base in step b)ii) is selected from the group consisting of trimethylamine, triethylamine, triisopropylamine, and N,N-diisopropylethylamine. In one embodiment, the base in step b)ii) is triethylamine.
[0041] In one embodiment, the process further comprises step c): i) Formula V
[0042] [ka] Formula V
[0043] reacting the compound of formula (I) with hydroxylamine in an organic solvent; ii) adding a base to the reaction mixture; and iii) isolating the compound of formula III from the reaction mixture. Including, In the formula, R 1 ~R 9 and n is as defined herein.
[0044] In one embodiment, the process further comprises step d): i) Formula VI
[0045] [ka] Equation VI
[0046] in an organic solvent with a compound of formula VII
[0047] [ka] Equation VI
[0048] Adding to the compound; ii) adding a base to the reaction mixture; and iii) isolating the compound of formula V from the reaction mixture. Including, In the formula, R 1 ~R 9 and n is as defined herein, and LG is a leaving group.
[0049] In one embodiment, the leaving group is selected from the group consisting of tosylate, mesylate, triflate, nosylate, brosylate, bromide, iodide and chloride.
[0050] In one embodiment, the process comprises step a) as outlined in Scheme 1. In one embodiment, the process comprises steps a) and b) as outlined in Scheme 1. In one embodiment, the process comprises steps a), b) and c) as outlined in Scheme 1. In one embodiment, the process comprises steps a), b), c), and d) as outlined in Scheme 1.
[0051] [ka] Scheme 1: Synthesis of compounds of formula I
[0052] In one embodiment, the compounds of formula I are inhibitors of the CIC-1 chloride ion channel.
[0053] In one embodiment, the compound of formula I is at least 80% pure, such as at least 90% pure, such as at least 95% pure, such as at least 96% pure, such as at least 97% pure, such as at least 98% pure.
[0054] In certain embodiments, the compounds or compounds for use according to the present disclosure may have an enantiomeric excess of >90%. In certain embodiments, the compounds or compounds for use according to the present disclosure may have an enantiomeric excess of >95% ee.
[0055] In one embodiment, the compound of formula I is: (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid is selected from the group consisting of:
[0056] In one aspect, the present disclosure provides a method for producing a method of making a digital camera comprising: i) according to the present invention (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid preparing a compound selected from the group consisting of: ii) formulating said compound into a pharmaceutical composition. The present invention relates to a process for the preparation of a pharmaceutical composition comprising:
[0057] In one aspect, the disclosure is directed to compounds of formula II as defined herein.
[0058] In one embodiment, the compound of formula II is: Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Methyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Ethyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; tert-Butyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Methyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Ethyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; tert-Butyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; and tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate is selected from the group consisting of:
[0059] The present disclosure is also directed, in part, to pharmaceutical compositions comprising the compound of formula I prepared by the process of the present disclosure. In one embodiment, the compound of formula I prepared by the process above may be included in a pharmaceutical composition. These compositions may also include one or more conventional pharma- ceutical compatible carriers. The compositions may include additional active ingredients / drugs or other ingredients to enhance the effectiveness of the composition.
[0060] Therefore, another aspect of the present disclosure is a process for preparing a pharmaceutical composition comprising a compound of formula I, characterized in that the compound of formula I is prepared by a process according to the invention.
[0061] Pharmaceutical compositions comprising a compound of formula I of the present disclosure and a pharma- ceutical compatible carrier constitute another aspect of the present invention.
[0062] Terms 1. Formula I
[0063] [ka] Formula I
[0064] 1. A process for the preparation of a compound of formula (I), Step a), i) Formula II
[0065] [ka] Formula II
[0066] reacting a compound of the formula (I) with an acid or a base; And ii) isolating the compound of formula I from the reaction mixture; Including, During the ceremony, -R 1 is selected from the group consisting of H, F, Cl, Br and I; -R 2 is C 1-5 Alkyl and C 3-5 cycloalkyl; -R 3 is selected from the group consisting of deuterium, F, Cl, Br and I; -R 4 is H, deuterium, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 3-5 cycloalkyl and C5 cycloalkenyl, each of which may optionally be one or more identical or different substituents R 7 may be substituted with; -R 5 optionally one or more identical or different substituents R 8 C replaced by 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 alkynyl, optionally one or more, identical or different, substituents R 8 C replaced by 3-6 cycloalkyl, optionally one or more, identical or different, substituents R 9 and optionally one or more, identical or different, substituents R 9 benzyl substituted with; -R 6 is H, deuterium, C 1-5 Alkyl and C 3-5 cycloalkyl; -R 7 are independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, and isocyanide; R 7 optionally one or more identical or different substituents R 8 C replaced by 3-5 cycloalkyl, optionally one or more, identical or different, substituents R 8 Replaced by OC 1-3 alkyl, optionally one or more, identical or different, substituents R 8SC replaced by 1-3 alkyl, optionally one or more, identical or different, substituents R 8 CH2-OC substituted with 1-3 Alkyl and optionally one or more, identical or different, substituents R 8 CH2-SC substituted with 1-3 is alkyl; -R 8 are independently selected from the group consisting of deuterium and F; -R 9 is independently selected from the group consisting of deuterium, methoxy, nitro, cyano, Cl, Br, I and F; and - n is an integer of 0, 1, 2 or 3, process.
[0067] 2.R 1 The process according to any of the preceding clauses, wherein is Cl or Br.
[0068] 3.R 1 The process according to any of the preceding clauses, wherein is Cl.
[0069] 4.R 1 The process according to any of the preceding clauses, wherein Br.
[0070] 5.R 2 is C1-5 alkyl.
[0071] 6.R 2 is selected from the group consisting of methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl.
[0072] 7.R 2The process according to any of the preceding clauses, wherein is ethyl.
[0073] 8.R 2 The process of any of the preceding clauses, wherein is prop-1-yl.
[0074] 9.R 2 The process according to any of the preceding clauses, wherein is prop-2-yl.
[0075] 10.R 2 The process according to any of the preceding clauses, wherein is but-1-yl.
[0076] 11.R 2 is 2-methyl-prop-2-yl.
[0077] 12.R 3 The process according to any of the preceding clauses, wherein F.
[0078] 13.R 3 The process according to any of the preceding clauses, wherein is deuterium.
[0079] 14.R 4 The process according to any of the preceding clauses, wherein
[0080] 15.R 4 optionally one or more identical or different substituents R 7 C replaced by 1-5 The process according to any of the preceding clauses, wherein R is alkyl.
[0081] 16.R 4 The process according to any of the preceding clauses, wherein
[0082] 17.R 4 The process according to any of the preceding clauses, wherein Et is
[0083] 18.R 4is -CH2F.
[0084] 19.R 4 The process according to any of the preceding clauses, wherein is cyclopropyl.
[0085] 20.R 5 optionally one or more identical or different substituents R 8 C replaced by 1-5 The process according to any of the preceding clauses, wherein R is alkyl.
[0086] 21.R 5 The process according to any of the preceding clauses, wherein
[0087] 22.R 5 The process according to any of the preceding clauses, wherein Et is
[0088] 23.R 5 is 2-methyl-prop-2-yl.
[0089] 24.R 6 The process according to any of the preceding clauses, wherein
[0090] 25.R 6 The process according to any of the preceding clauses, wherein:
[0091] 26.R 6 But, C 1-5 The process according to any of the preceding clauses, wherein R is alkyl.
[0092] 27.R 6is selected from the group consisting of methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl.
[0093] 28.R 7 The process according to any of the preceding clauses, wherein is deuterium.
[0094] 29.R 7 The process according to any of the preceding clauses, wherein F.
[0095] 30.R 7 optionally one or more identical or different substituents R 8 C replaced by 3-5 The process according to any of the preceding clauses, wherein R is cycloalkyl.
[0096] 31.R 4 is a substituent R 7 C replaced by 1-5 is alkyl, R 7 optionally one or more identical or different substituents R 8 C replaced by 3-5 The process according to any of the preceding clauses, wherein R is cycloalkyl.
[0097] 32. The process according to any of the preceding clauses, wherein n=0.
[0098] 33. The process according to any of the preceding clauses, wherein n=1.
[0099] 34. The process according to any of the preceding clauses, wherein n=2.
[0100] 35. The process according to any of the preceding clauses, wherein n=3.
[0101] 36. The process according to any of the previous clauses, wherein the compound of formula II is reacted with a base.
[0102] 37. The process according to any of the preceding clauses, wherein the compound of formula II is reacted with an acid.
[0103] 38. The process according to any of the preceding clauses, wherein the compound of formula II is reacted with concentrated acid.
[0104] 39. The process according to any of the previous clauses, wherein the compound of formula II is reacted with an acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, hydrochloric acid and sulfuric acid or mixtures thereof.
[0105] 40. The process according to any of the preceding clauses, wherein the compound of formula II is reacted with concentrated formic acid.
[0106] 41. The process according to any of the preceding clauses, wherein the compound of formula II is reacted with concentrated acetic acid.
[0107] 42. The process according to any of the preceding clauses, wherein the compound of formula II is reacted with a mixture of concentrated formic acid and concentrated acetic acid.
[0108] 43. The process according to any of the preceding clauses, wherein step a) is carried out at a temperature between 70°C and 140°C, such as between 80°C and 130°C, such as between 90°C and 120°C.
[0109] 44. The process according to any of the preceding clauses, wherein the reaction time in step a) is from 12 hours to 96 hours, such as from 24 hours to 72 hours, such as from 36 hours to 60 hours.
[0110] 45. The process according to any of the preceding clauses, wherein the amount of acid used in step a)i) is from 3 mL per gram of starting material to 15 mL per gram of starting material.
[0111] 46. The process according to any of the previous clauses, wherein the compound of formula I is isolated from the reaction mixture in step b) by adding water and extracting the product into an organic solvent.
[0112] 47. The process according to any of the previous clauses, wherein the compound of formula I is isolated from the reaction mixture in step b) by adding water and extracting the product into an organic solvent selected from the list consisting of toluene, ethyl acetate, isopropyl acetate and tert-butyl methyl ether.
[0113] 48. The process according to any of the preceding clauses, wherein the compound of formula I is purified by crystallization from an organic solvent.
[0114] 49. The process according to any of the previous clauses, wherein the compound of formula I is purified by crystallization from an organic solvent selected from the list consisting of toluene, ethyl acetate, isopropyl acetate and tert-butyl methyl ether.
[0115] 50.Step b), i) Formula III
[0116] [ka] Formula III
[0117] reacting the compound of formula (I) with N-chlorosuccinimide in an organic solvent; ii) Formula IV
[0118] [ka] Formula IV
[0119] and a base to the reaction mixture; and iii) isolating the compound of formula II from the reaction mixture. Further comprising: In the formula, R 1 ~R 9and n is as defined in clause 1.
[0120] 51. The process according to any of the preceding clauses, wherein the solvent in step b)i) is dimethylformamide (DMF).
[0121] 52. The process according to any of the previous clauses, wherein the compound of formula IV is selected from the group consisting of ethyl vinyl ether, n-butyl vinyl ether and tert-butyl vinyl ether.
[0122] 53. The process according to any of the previous clauses, wherein the base in step b) ii) is selected from the group consisting of trimethylamine, triethylamine, triisopropylamine and N,N-diisopropylethylamine.
[0123] 54. Process c), i) Formula V
[0124] [ka] Formula V
[0125] reacting the compound of formula (I) with hydroxylamine in an organic solvent; ii) adding a base to the reaction mixture; and iii) isolating the compound of formula III from the reaction mixture. Further comprising: In the formula, R 1 ~R 9 and n is as defined in claim 1.
[0126] 55. The process according to any of the previous clauses, wherein the organic solvent in step c)i) is an alcohol.
[0127] 56. The process according to any of the previous clauses, wherein the organic solvent in step c)i) is an alcohol selected from the group consisting of methanol, ethanol, propanol, n-butanol and tert-butanol.
[0128] 57. The process according to any of the preceding clauses, wherein the base in step c) ii) is selected from the group consisting of pyridine, trimethylamine, triethylamine, triisopropylamine and N,N-diisopropylethylamine.
[0129] 58.Step d), i) Formula VI
[0130] [ka] Equation VI
[0131] in an organic solvent with a compound of formula VII
[0132] [ka] Equation VI
[0133] Adding to the compound; ii) adding a base to the reaction mixture; and iii) isolating the compound of formula V from the reaction mixture. Further comprising: In the formula, R 1 ~R 9 and n is as defined herein and LG is a leaving group.
[0134] 59. The process according to any of the previous clauses, wherein the leaving group (LG) of formula VI is selected from the group consisting of tosylate, mesylate, triflate, nosylate, brosylate, bromide, iodide and chloride.
[0135] 60. The process according to any of the preceding clauses, wherein the leaving group (LG) of formula VI is a tosylate.
[0136] 61. The process of any of the previous clauses, wherein the organic solvent is selected from the group consisting of pentane, hexane, heptane, toluene, xylene, dichloromethane, tetrahydrofuran and acetonitrile.
[0137] 62. The process according to any of the preceding clauses, wherein the base in step d) ii) is an inorganic base.
[0138] 63. The process according to any of the previous clauses, wherein the base in step d) ii) is an inorganic base selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, lithium hydroxide, sodium hydroxide and potassium hydroxide.
[0139] 64. A compound of formula I: (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid The process of any of the preceding clauses, wherein the compound is selected from the group consisting of:
[0140] 65. The process according to any of the previous clauses, wherein the compound of formula I is an inhibitor of the CIC-1 chloride ion channel.
[0141] 66. The process according to any of the preceding clauses, wherein the compound of formula I is at least 80% pure, such as at least 90% pure, such as at least 95% pure, such as at least 96% pure, such as at least 97% pure, such as at least 98% pure.
[0142] 67. A process for the preparation of a pharmaceutical composition, comprising: i) as provided for in any of the preceding clauses (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid preparing a compound selected from the group consisting of: ii) formulating said compound into a pharmaceutical composition. The process includes:
[0143] Working Example material and method NMR spectra 1 H-NMR spectra were recorded on either a Jeol LA400 (400 MHz) spectrometer and were calibrated using the residual non-deuterated solvent as an internal reference (7.24 ppm for CHCl3).
[0144] LCMS method Instrumentation: Agilent 1260 Infinity Series LC (high pressure degasser, binary pump, autosampler and column oven) with an Agilent 1100 DAD detector scanning from 210 nm to 315 nm. Mass detection was obtained on an API 2000 mass spectrometer (electrospray). Column: Agilent Poroshell 120EC-C18 (2.7 μm, 3.0 × 50 mm). Conditions: 0.1% v / v formic acid in water [eluent A]; MeCN [eluent B]; flow rate 0.8 mL / min and equilibration time between samples of 1.5 min. gradient:
[0145] [Table 1]
[0146] Chiral SCF method Compounds were analyzed using a Waters ACQUITY Ultra Performance Convergence Chromatography (UPC2) system equipped with a binary solvent delivery pump, an autosampler, a column oven (CM-30S), a backpressure regulator, and a diode array detector. Column: Lux A1 (4.6 mm x 250 mm, 5 μm). Conditions: 40°C, 4mL / min, isocratic 15:85 EtOH:CO2 (0.1% v / v TFA), 125BarG.
[0147] Example 1: Synthesis of (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid (S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid B.6 was prepared using the schematic diagram shown below.
[0148] [ka]
[0149] Synthesis of methyl (S)-2-(4-bromo-2-formylphenoxy)propanoate B.3 5-Bromo-2-hydroxybenzaldehyde B.1 (9.26 g, 46.10 mmol) was added to a stirred solution of methyl (R)-2-(tosyloxy)propanoate B.2 (11.90 g, 46.10 mmol) in hexane (180 mL) and the resulting mixture was heated to 80° C. until dissolved. Potassium carbonate (12.74 g, 92.20 mmol) was added to the reaction mixture and stirred at 80° C. for 36 h and at room temperature for 60 h.
[0150] The solvent was removed in vacuo and the residue was partitioned between water (400 mL) and ethyl acetate (400 mL). The aqueous phase was extracted with additional ethyl acetate. The organic phases were combined, washed with water (2×300 mL) and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a pale yellow oil. This crude material was purified via silica gel flash column chromatography using heptane:ethyl acetate 10-20% as the solvent system to give the desired product, methyl (S)-2-(4-bromo-2-formylphenoxy)propanoate B.3, as a colorless oil that solidified overnight (8.08 g, 62% yield).
[0151] 1H NMR(400MHz,CDCl3)δ 10.54(s,1H),7.94(d,J=2.7Hz,1H),7.56(dd,J=8.9,2.7Hz,1H),6.71(d,J=8.9Hz,1H),4.84(q,J=6.8Hz,1H),3.74(s,3H),1.68(d,J=6.8Hz,3H). LC / MS (Agilent) m / z is 286.8 (M+H) in 2.54 minutes + .
[0152] Synthesis of methyl (S,E)-2-(4-bromo-2-((hydroxyimino)-methyl)phenoxy)propanoate B.4 Hydroxyamine hydrochloride (1.87 g, 26.90 mmol) was added under nitrogen to a stirred solution of methyl (S)-2-(4-bromo-2-formylphenoxy)propanoate B.3 (7.25 g, 26.90 mmol) in methanol (150 mL) precooled to −40° C. Then pyridine (2.6 mL, 29.60 mmol) was added dropwise to the mixture and stirred at that temperature for 1 h. The reaction mixture was stored at 4° C. overnight.
[0153] The reaction mixture was warmed to room temperature and poured into water (400 mL). The solution was extracted with ethyl acetate (2×400 mL). The organic phases were combined, washed with water (2×300 mL) and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the desired product, methyl (S,E)-2-(4-bromo-2-((hydroxyimino)-methyl)phenoxy)propanoate B.4 as a white solid (8.20 g, quantitative yield).
[0154] 1H NMR(400MHz,CDCl3)δ 8.49(s,1H),7.87(d,J=2.6Hz,1H),7.35(dd,J=8.8,2.6Hz,1H),6.61(d,J=8.8Hz,1H),4.74(q,J=6.8Hz,1H),3.72(s,3H),1.63(d,J=6.8Hz,3H). LC / MS (Agilent) m / z is 301.9 (M+H) in 2.42 minutes + .
[0155] Synthesis of methyl (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 N-Chlorosuccinimide (3.90 g, 28.95 mmol) was added to a solution of methyl (S,E)-2-(4-bromo-2-((hydroxyimino)methyl)phenoxy)propanoate B.4 (7.95 g, 26.40 mmol) in dimethylformamide (200 mL) at room temperature, followed by a 1 M solution of hydrochloric acid (1 mL aqueous solution). The resulting reaction mixture was stirred at room temperature for 75 min. After that time, the mixture was cooled to 0° C. and triethylamine (4.42 mL, 31.70 mmol) was added to it, followed by butyl vinyl ether (4.1 mL, 31.70 mmol). The reaction mixture was stirred at room temperature for 3.5 h.
[0156] The reaction mixture was poured into water (350 mL), acidified to pH 5 with a 1 M solution of hydrochloric acid, and extracted with tert-butyl methyl ether (2 x 350 mL). The organic phases were combined, washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the desired product, methyl (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 (approximately 1:1 mixture of diastereoisomers) as a yellow oil (10.30 g, 98% yield).
[0157] 1H NMR (400 MHz, CDCl3) δ 7.99 and 7.97 (two d, J = 2.5 Hz, 1H), 7.37 (dd, J = 8.9, 2.5 Hz, 1H), 6.63 and 6.61 (two d, J = 8.9 Hz, 1H), 5.62 (m, 1H), 4.78 (m, 1H), 3.81 (m, 1H), 3.73 and 3.71 (two s, 3H), 3.59 (m, 1H), 3.48 (m, 1H), 3.35 and 3.31 (two dd, J = 13.4, 1.5 Hz, 1H), 1.61 (d, J = 6.8 Hz, 3H), 1.56 (m, 2H), 1.35 (m, 2H), 0.90 and 0.89 (two t, J = 7.4 Hz, 3H). LC / MS (Agilent) m / z was 399.9 (M+H) at 2.91 min. + .
[0158] Synthesis of (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid B.6 A solution of ethyl (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 (9.15 g, 22.90 mmol) in aqueous formic acid (90%) (100 mL, 2.39 mol) was heated at 100° C. for 6 h.
[0159] The reaction mixture was cooled to room temperature and the solvent was removed in vacuo. The crude material was azeotroped with acetonitrile and dried under vacuum for 1 h at 40° C. The isolated oil was fractionated with tert-butyl methyl ether and water. The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give a yellow oil. The oil was triturated with dichloroethane (20 mL) and hexanes (400 mL) and the isolated solid was dried in a vacuum oven overnight to give the desired product, (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid B.6, as a beige solid (5.52 g, 78% yield).
[0160] 1H NMR(400MHz,CDCl3)δ 8.49(d,J=1.8Hz,1H),7.77(d,J=2.4Hz,1H),7.53(dd,J=8.8,2.4Hz,1H),6.90(d, J=8.8Hz,1H),6.78(d,J=1.8Hz,1H),4.91(q,J=6.9Hz,1H),1.73(d,J=6.9Hz,3H). LC / MS (Agilent) m / z is 312.0 (M+H) in 2.40 minutes + .
[0161] The overall yield was 48% starting from 5-bromo-2-hydroxybenzaldehyde B.1 and the product was >98% pure as judged by LC / MS and 1H NMR. Chiral SCF method: (S)-enantiomer 2.12 min; (R) enantiomer 2.79 min.
[0162] Example 2: Synthesis of (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid Synthesis of methyl (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 DMF (595 mL) was added to methyl (S,E)-2-(4-bromo-2-((hydroxyimino)methyl)phenoxy)propanoate B.4 (119 g) and the temperature was adjusted to 20 °C. N-chlorosuccinimide (16.0 g, 0.3 equiv.) was added and the reaction was stirred at 15-30 °C for 20 min. N-chlorosuccinimide (4 x 10.5 g, 4 x 0.2 equiv.) was added in four equal portions every 5 min while maintaining the temperature at 20-30 °C and the reaction was stirred at 15-30 °C for 20 min. The reaction was cooled to 0-5 °C and butyl vinyl ether (56.6 mL, 1.1 equiv.) was added followed by triethylamine (54.9 mL, 1.0 equiv.) dropwise over 1 h at 0-5 °C. The reaction was stirred at 0-5° C. for 12 h, then water (1.19 L) was added over 5 min. The product was extracted with tert-butyl methyl ether (2×600 mL) and the organic phase was washed with 10% w / w brine (2×350 mL), dried over magnesium sulfate, filtered and concentrated to give methyl (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 as an amber oil as a ca. 1:1 mixture of diastereoisomers (157.1 g, quantitative).
[0163] Synthesis of (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid B.6 (2S)-2-(4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy)propanoate B.5 (151 g) was dissolved in acetic acid (755 mL) and water (226 mL) was added at 15-25° C. The reaction was heated at reflux (approximately 107° C.) for 48 hours or until process control indicated the reaction was complete. The reaction was cooled to 15-25° C. and water (1.5 L) was added. The product was extracted with tert-butyl methyl ether (755 mL, then 450 mL) and the combined organic phase was washed with 10% w / w brine (3×450 mL). The organic phase was distilled to leave approximately 4 volumes and then toluene (1.5 L) was added. The organic phase was distilled to leave approximately 5 volumes and then toluene (750 mL) was added. The organic phase was distilled leaving about 4 volumes, then cooled to 80-90 °C and filtered. The organic phase was cooled to 50-55 °C and seeded. The solution was stirred at 50-55 °C for 30 min, cooled to 0-5 °C over 12 h, stirred at 0-5 °C for 5 h, then filtered and washed with toluene (150 mL) and n-heptane (2 x 300 mL). The solid was dried at 40 °C until there was no further change in mass to give (2S)-2-(4-bromo-2-(isoxazol-3-yl)phenoxy)propanoic acid B.6 as a beige solid (83.9 g, 71%) with >98% purity as determined by LC / MS and 1H NMR and >98% enantiomeric excess as determined by chiral HPLC.
[0164] Example 3: Screening of compounds against the human isoform of ClC-1 expressed in CHO cells using automated patch-clamp The research goal of these experiments was to evaluate how compounds affect the open probability and current amplitude of human ClC-1 channels expressed in CHO cells. Experiments were performed using an automated patch clamp system that allows for high-throughput testing of whole-cell patches, with both intracellular and extracellular addition of compounds.
[0165] Automated Voltage Clamp Measurements Automated whole-cell patch clamp experiments were performed at room temperature using the Qpatch16 system (Sophion Bioscience, Ballerup, Denmark). Data acquisition and analysis were performed in Qassay software (ver. 5.6, Odense).
[0166] Voltage protocols and analysis of whole blood CIC-1 currents To elicit CIC-1 currents in whole-cell patches, the membrane potential was first stepped from a holding potential of -30 mV to +60 mV for 100 ms, followed by various test voltages (sweeps) ranging from +120 mV to -140 mV for 300 ms. To obtain tail currents, the membrane potential was stepped to -100 mV after each test voltage for 300 ms, and then relaxed to -30 mV for 2 s between sweeps (Fig. 1). I / V relationships for whole-cell instantaneous and steady-state current amplitudes were obtained by plotting the average current density at the beginning and end of the 300 ms steps against the membrane potential (Fig. 2).
[0167] To determine the relative whole-cell open probability (P), the instantaneous tail currents were normalized to the maximum tail current obtained after the most positive voltage step and plotted against the test voltage. Plots of the normalized tail currents from each whole-cell patch were then fitted to a Boltzmann function, allowing the determination of the half-activation voltage (V 1 / 2 , Figure 3).
[0168] solution For automated patch clamp experiments, the extracellular solution contained 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 4 mM KCl, 145 mM NaCl, 10 mM glucose, pH was adjusted to 7.4 with NaOH (2 M). Osmolarity was adjusted to approximately 320 using sucrose.
[0169] The intracellular solution contained 80 mM CsF, 60 mM CsCl, 5 / 1 mM KOH / EGTA, 10 mM HEPES, 10 mM NaCl, pH was adjusted to 7.2 with NaOH (2 M), and osmolarity was adjusted to approximately 320 mOsm using sucrose.
[0170] Cell line information The cells used in the patch clamp experiments were Chinese Hamster Ovary cells (CHO) constitutively expressing the human CIC-1 channel. The amino acid sequence encoded by the cDNA used to generate this cell line was identical to the sequence translated for GenBank accession number NM_000083.2. The cells were produced in a cryopreserved form by Charles River (catalog CT6175, Cleveland OH, USA). Experiments were performed on the cells directly after thawing (3 × 10 6 cells were used in each experiment).
[0171] Testing Protocol To evaluate the effect of compounds on CIC-1, the half-activation voltage V 1 / 2 was determined from a whole-cell patch where compound was added to the intracellular solution, followed by a control cell patch where only vehicle was added to the intracellular solution. 1 / 2 In addition, the effects of compounds added extracellularly were compared to V before and after the extracellular solution was exchanged to contain the compounds. 1 / 2 and steady-state current amplitudes were determined.
[0172] Difference in half-activation voltage of CIC-1 channels, ΔV 1 / 2 was determined as the difference between cell patches treated intracellularly with compound and control cell patches and is reported in Table 1 below. 1 / 2 A positive shift in reflects CIC-1 channel inhibition by the tested compounds. A P value of <0.05 is considered significant.
[0173] Table 1: Half-activation voltage V 1 / 2 Shift in [Table 2]
[0174] Example 4: Measuring muscle contraction characteristics in situ Isometric hindlimb force was measured in 12 week old female Lewis rats in the presence and absence of compound.
[0175] Rats were anesthetized with isoflurane (2–4%), intubated, and subsequently connected to a microventilator (Microvent 1, Hallowell EMC, US). Two stimulating electrodes were inserted through the skin to stimulate the sciatic nerve. A small incision was made proximal to the ankle to expose the Achilles tendon, which was tied with a cotton string and connected to a force transducer (Fort250, World Precision Instruments) at an adjustable position (vernier control). The Achilles tendon was then cut distal to the attached cotton string. Rats were placed on a heating pad and the foot was taped to a footplate to prevent movement artifacts from contraction of the ankle dorsiflexors.
[0176] Muscle contractile properties were assessed by applying electrical current (under highest voltage conditions) to the nerve and recording the force generated by the muscle. When assessed with 2 Hz stimulation, the muscle was stretched until maximal force was obtained. Isometric force was measured at 12 Hz (twitch), 10 pulses every 30 s, and at 80 Hz (tetanic), 1 s (80 pulses) every 5 min. This stimulation pattern was employed throughout the experiment, except in some cases where the 80 Hz stimulation was replaced by 12 Hz (10 pulses). Neuromuscular transmission was partially inhibited by continuous infusion of cisatracurium (Nimbex, GlaxoSmithKline) at a concentration of 0.1 mg / kg with an adjustable injection rate adjusted individually for each animal to obtain a level of inhibition of approximately 50% of the force generated with 12 Hz stimulation for the fourth pulse. When the level of neuromuscular inhibition was stable, the test article was injected iv at the selected concentration. The effect of the test article was evaluated for its ability to increase the force generated from the applied stimulation pattern. Effects were assessed by the ability to increase force by itself (tetanic, 80 Hz, stimulation) and the ratio between individual twitch peaks (12 Hz stimulation). Effects were monitored for at least 1 hour after injection of the test article. In addition, the time from test article injection to maximum effect on force (both twitch and tetanic) was recorded, and, if possible, the time until the effect disappeared (return to baseline) was recorded. When appropriate, the injection of neuromuscular blocker was discontinued while continuing the stimulation pattern, and the return of force to control levels was monitored. Animals were sacrificed by cervical dislocation while remaining fully sedated.
[0177] (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid was administered at 24.6 mg / kg iv. The mean increase in tetanic force was 46.2% (3 experiments). 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid was administered at 44.8 mg / kg iv. The mean increase in tetanic force was 57.7% (2 experiments).
[0178] This demonstrates that compounds of the invention are able to restore force to muscles in vivo that are partially inhibited by neuromuscular blockers.
Claims
1. Formula I 【Chemistry 1】 1. A process for the preparation of a compound of the formula i) Formula II 【Chemistry 2】 is reacted with an acid or base, And ii) the compound of formula I is isolated from the reaction mixture; It comprises step a), During the ceremony, -R 1 is selected from the group consisting of H, F, Cl, Br and I; -R 2 is C 1-5 Alkyl and C 3-5 cycloalkyl; -R 3 is selected from the group consisting of deuterium, F, Cl, Br and I; -R 4 is H, deuterium, C 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 3-5 Cycloalkyl and C 5 cycloalkenyl, each of which is optionally selected from the group consisting of one or more, identical or different, substituents R 7 may be substituted with; -R 5 optionally one or more identical or different substituents R 8 C substituted with 1-5 Alkyl, C 2-5 Alkenyl, C 2-5 alkynyl, optionally one or more identical or different substituents R 8 C substituted with 3-6 cycloalkyl, optionally one or more, identical or different, substituents R 9 and optionally one or more, identical or different, substituents R 9 benzyl substituted with; -R 6 is H, deuterium, C 1-5 Alkyl and C 3-5 cycloalkyl; -R 7 is deuterium, tritium, F, Cl, Br, I, CN, isocyanide, optionally one or more identical or different substituents R 8 C substituted with 3-5 cycloalkyl, optionally one or more, identical or different, substituents R 8 O-C substituted with 1-3 alkyl, optionally one or more, identical or different, substituents R 8 S-C substituted with 1-3 alkyl, optionally one or more, identical or different, substituents R 8 CH substituted with 2 -O-C 1-3 Alkyl and optionally one or more identical or different substituents R 8 CH substituted with 2 -S-C 1-3 independently selected from the group consisting of alkyl; -R 8 is independently selected from the group consisting of deuterium and F; -R 9 is independently selected from the group consisting of deuterium, methoxy, nitro, cyano, Cl, Br, I and F; and - n is an integer 0, 1, 2 or 3; process.
2. R 1 The process of claim 1 , wherein is Cl or Br.
3. R 2 But, C 1-5 3. The process of claim 1, wherein the alkyl group is an alkyl group.
4. R 3 The process of claim 1 , wherein
5. R 4 optionally one or more identical or different substituents R 7 C substituted with 1-5 5. The process of claim 1, wherein the alkyl group is an alkyl group.
6. R 5 optionally one or more identical or different substituents R 8 C substituted with 1-5 6. The process of claim 1, wherein the alkyl group is an alkyl group.
7. R 6 The process of claim 1 , wherein
8. 8. The process of claim 1, wherein n=0.
9. 9. The process according to any one of claims 1 to 8, wherein the compound of formula II is reacted with an acid.
10. The process of claim 1, wherein the compound of formula II is reacted with an acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, hydrochloric acid and sulfuric acid or mixtures thereof.
11. 11. The process according to any one of claims 1 to 10, wherein the compound of formula II is reacted with a base.
12. 12. The process according to any of claims 1 to 11, wherein the reaction time of step a)i) is from 12 hours to 96 hours.
13. 13. The process according to any of claims 1 to 12, wherein the compound of formula I is purified by crystallization from an organic solvent selected from the list consisting of toluene, ethyl acetate, isopropyl acetate and tert-butyl methyl ether.
14. 14. The process according to any of claims 1 to 13, wherein the compound of formula I is an inhibitor of the CIC-1 chloride ion channel.
15. The compound of formula I, (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid 15. The process according to any one of claims 1 to 14, wherein the compound is selected from the group consisting of:
16. i) Formula III 【Chemistry 3】 is reacted with N-chlorosuccinimide in an organic solvent; ii) Formula IV 【Chemistry 4】 and a base are added to the reaction mixture; and iii) The compound of formula II is isolated from the reaction mixture. Further comprising step b), In the formula, R 1 ~R 9 and n is as defined in claim 1.
17. Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Methyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Ethyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; tert-Butyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Methyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Methyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; Ethyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; Ethyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; Ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropyl acetate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate; tert-Butyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-Butyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate; tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; and tert-Butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate 2. A compound of formula (II) as defined in claim 1 selected from the group consisting of:
18. 1. A process for the preparation of a pharmaceutical composition comprising: i) preparing a compound of formula I according to any one of the processes of claims 1 to 16, said compound being (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; 2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid; (2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid; (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid and ii) formulating said compound into a pharmaceutical composition The process includes:
Citation Information
Patent Citations
JPP7310071B
Compounds for use in treating neuromuscular disorders
WO2016202341A1
